HOLX Beats F1Q Expectations, Raises Guidance
Analysts at Leerink Swann & Co maintain their "outperform" rating on Hologic Inc (NASDAQ: HOLX), while raising their estimates for the company.
Hologic has reported its F1Q results ahead of expectations. HOLX raised its revenue
guidance for FY10 to $1.640B-$1.665B from $1.625B-$1.650B and EPS guidance to $1.16-$1.20 from $1.15-$1.19. “We view this $0.01 increase as conservative given the $0.03 beat in F1Q,” the analysts mention.
“Management highlighted plans to develop an ultra low cost (less than $100K) digital mammography system for emerging markets over the next few years, gain a foothold in CT/NG testing (10-15% share long-term), and continue acquisitions in GYN Surgical,” the analysts add. Leerink Swann & Co has raised its EPS estimate for FY2010 from $1.19 to $1.20.
